Can a laser drill through the Heart's hardest blockages?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects of age \> 18 years old. 2. Stenosis lesion ≥ 70% diameter stenosis as assessed by visual estimation. 3. Visionally estimated the reference vessel diameter to be ≥ 2.0 mm to allow the passage of guidewire. 4. Subject has at least one non-crossable and/or non-dilatable stenosis lesion. Target lesion belongs to one of the following conditions: 1. Coronary artery lesions previously treated with Drug-Eluting Stent (DES) or Bare-Metal Stent (BMS), including in-stent restenosis or stent under-expansion; or 2. Chronic Total Occlusion (CTO) with an estimated occlusion time of ≥ 3 months and with TIMI flow 0-1 confirmed by Coronary angiography; or 3. De novo coronary lesions with failed balloon angioplasty, defined as residual diameter stenosis \>50% and/or TIMI flow 0-2 after high-pressure balloon inflations, confirmed by coronary angiography. 5. Subject can understand the purpose of the NEON study and has signed voluntarily the informed consent form and is agreeing to the scheduled follow up requirements Exclusion Criteria: 1. Evidence of acute ischemic events 2. Evidence of severe valvular pathology, based on echocardiogram result according to the investigator's assessment. 3. Evidence of \< 30% Left Ventricular Ejection Fraction (LVEF) based on Echocardiogram results 4. Cardiogenic and non-cardiogenic shock within 3 months. 5. Active bleeding or coagulopathy 6. Previous coronary angioplasty within 3 months of the index procedure 7. Patients participating in another trial for which the primary endpoint has not be reached 8. Acute or Chronic renal failure, Impaired renal function (serum creatinine \> 2.5 mg/dl or 221 umol/l) determined within 72 hours prior to index procedure. 9. Known allergies to the following: Aspirin, Clopidogrel or Ticlopidine, Heparin, Sirolimus or its derivatives, contrast agent (that cannot be adequately pre-medicated), or any metal 10. Planned surgery within 6 months of enrolment in this study 11. Life expectancy is less than 6 months 12. Patients known to be suffering from substance abuse (alcohol or drug) 13. Patients with any other significant co-morbid illness which, in the opinion of the investigator, are not conducive to inclusion in the study. 14. Known or suspected Pregnancy and breastfeeding population. Childbearing potential and unwilling to use contraception to control. 15. Patients not willing to provide written informed consent 16. In the investigators' opinion, subjects will not be able to comply with the follow-up requirements. 17. Patients with bifurcation and Ostial lesions